destiny-breast04: t-dxd provides significant improvement in os pfs in her2-low mbc
Published 2 years ago • 3.1K plays • Length 5:11Download video MP4
Download video MP3
Similar videos
-
0:56
destiny-breast04: t-dxd for patients with her2-low mbc
-
2:30
destiny-breast04: t-dxd in her2-low breast cancer regardless of molecular markers
-
1:14
destiny-breast04: exploring t-dxd and io combinations in her2-low breast cancer
-
2:01
destiny-breast04: practice-changing results for her2-low breast cancer
-
1:08
destiny-breast04: a ground-breaking trial in her2-low breast cancer
-
1:08
updated survival results of destiny-breast03: t-dxd vs t-dm1 in her2 metastatic breast cancer
-
2:12
trastuzumab deruxtecan in her2-low advanced breast cancer | nejm
-
4:15
debbrah: t-dxd in her2 or her2-low advanced breast cancer with cns involvement
-
11:12
her2-low breast cancer: destiny or good science?
-
5:05
anti-her2 mechanisms of approved her2 inhibitors
-
5:45
her2-positive breast cancer: a paradigm shift in diagnosis and therapy
-
2:30
patient-reported outcomes from destiny-breast04
-
1:32
destiny-breast15: t-dxd in patients with hr hr- and her2-low or her2 ihc 0 metastatic breast cancer
-
3:11
destiny-breast06: determining her2-(ultra)low status in hr mbc
-
2:58
updated analysis of destiny-gastric02: t-dxd in her2 gej cancer who progressed with trastuzumab
-
2:38
highlights on t-dxd in pretreated her2-expressing solid tumours : the destiny-pantumor02 study
-
1:08
destiny-breast02: t-dxd in her2 metastatic breast cancer previously treated with t-dm1
-
1:16
her2-low expression in breast cancer
-
3:09
destiny-breast02: high levels of efficacy of t-dxd in previously treated her2 breast cancer
-
3:15
dr curigliano on the efficacy of t-dxd in her2-low and her2-ultralow breast cancer
-
5:40
trastuzumab deruxtecan doubles pfs in metastatic breast cancer with low her2 expression
-
1:23
tuxedo-1: qol and neurocognitive function in her2-positive bc w/ brain metastasis treated with t-dxd